Search results (61)
« Back to NewsTyphoid vaccine trial confirms sustained protection for older children
10 October 2024
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
Ground-breaking research revealed in new video
17 September 2024
The Oxford Vaccine Group has released new footage of ground-breaking research aimed at revolutionising vaccine design, particularly for those most vulnerable to diseases like flu and COVID-19.
Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus
12 July 2024
Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.
Professor Teresa Lambe OBE elected to the Fellowship of the Academy of Medical Sciences
21 May 2024
Awards & Appointments Department Public Engagement Research
Professor Teresa Lambe OBE, Calleva Head of Immunology at the Oxford Vaccine Group, and Principal Investigator at the Pandemic Sciences Institute, has been elected a Fellow of the Academy of Medical Sciences, one of the most prestigious awards in the field.
Professor Sir Andrew Pollard elected to the Fellowship of the Royal Society
16 May 2024
Awards & Appointments Department Research
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.
Ground-breaking study reveals how COVID-19 vaccines prevent severe disease
3 May 2024
COVID-19 Methods Publication Research
A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
New trial to study how the human immune system adapts to ‘tolerate’ malaria parasites
18 March 2024
Department Methods Public Engagement Research
Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.
Oxford University Professors to lecture on new course in 'Translational Science' at three Brazilian institutions
1 February 2024
The Department of Paediatrics at the University of Oxford, has entered into an agreement with three Brazilian Universities, to contribute to the delivery of an undergraduate course in ‘Translational Science’, starting in 2024.
FCDO Minister meets with vaccine researchers
25 January 2024
Department Public Engagement Research
Researchers from the Department of Paediatrics today welcomed the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.
First in-human vaccine trial for Nipah virus
11 January 2024
The University of Oxford has launched a new clinical trial to test a vaccine against the deadly Nipah virus.
Oxford Vaccine Group receives £7.8 million in research funding to fight pandemic and epidemic threats
12 December 2023
Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of £7,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential.
OVG Researcher awarded prestigious NIHR Professorship
20 November 2023
Awards & Appointments COVID-19 Department Methods Research
Daniela Ferreira, Professor of Respiratory Infection and Vaccinology at the University of Oxford’s Department of Paediatrics and the Department of Clinical Sciences at the Liverpool School of Tropical Medicine has been awarded one of six prestigious Research Professorships by the National Institute of Health and Care Research (NIHR).
CEPI funding announced for development of vaccine prototype
2 November 2023
Awards & Appointments COVID-19 Research
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced the launch of a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly haemorrhagic fevers with epidemic and pandemic potential.
Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines
25 October 2023
COVID-19 Methods Public Engagement Research
A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.
First vaccine trial in older people launched for Middle East Respiratory Syndrome (MERS)
18 September 2023
COVID-19 Methods Public Engagement Research
Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).
First in-human trials commence for CCHF vaccine
13 September 2023
COVID-19 Methods Public Engagement Research
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
University of Oxford partners with CEPI to counter the threat of future pandemics
30 August 2023
COVID-19 Department Public Engagement Research
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.
New survey launched to explore the acceptability of the Gonococcal Controlled Human Infection Model in UK men.
13 January 2023
Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.
Oxford Ebola vaccine manufactured and shipped in record time by SII
19 December 2022
More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.
From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford
7 December 2022
Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed